Teduglutide: Bringing New Hope To Patients With Short Bowel Syndrome
Teduglutide is sold under the brand names Revestive (EU) and Gattex (USA), and is a 33 yuan peptide and glucagon-like peptide-2 (GLP-2) analogue used to treat short bowel syndrome.
What is Short Bowel Syndrome?
Short bowel syndrome is a disease caused by extensive small bowel resection or loss of function, resulting in a significant decrease in the patient’s intestinal absorption capacity.
The effective absorption area of the small intestine decreases, requiring patients to rely on parenteral nutrition (PN) for long-term survival.
However, long-term use of PN can bring a series of health risks, including infection, liver function damage, and decreased quality of life.
Therefore, finding treatment methods that can help improve intestinal absorption and reduce PN dependence has become an urgent need for SBS patients.
Teduglutide: Bringing New Hope to Short Intestine Patients
Tendaglutide is a GLP-2 analogue that promotes intestinal adaptation, helps restore intestinal function, and significantly improves nutrient absorption.
GLP-2 is a hormone secreted by the intestine that promotes the growth and repair of the small intestine, enhancing its absorption capacity.
Gattex stimulates the growth and repair of intestinal cells by simulating the action of this natural hormone, reducing the demand for PN and thus improving the quality of life of SBS patients.
Clinical Outcome: Teduglutide Improves Patients’ Quality Of Life
In a series of clinical trials, teduglutide has been proven to have significant therapeutic effects.
The data shows that it can significantly reduce patients’ dependence on parenteral nutrition and improve intestinal absorption function.
For SBS patients who rely on PN for a long time, the use of Gattex Teduglutide can effectively reduce the frequency and dosage of PN infusion, alleviate patients’ pain, and improve their nutritional status.
More importantly, the use of it has helped improve the quality of life for patients.
After receiving treatment with it, patients typically exhibit more stable weight, increased energy levels, and improved intestinal function.
All of this enables SBS patients to lead a more normal life.
Future Prospects: Bringing Hope To SBS Patients
The approval of the marketing of teduglutide not only provides better treatment options for SBS patients but also provides new ideas for research and development in related fields.
As the world’s first human glucagon-like peptide-2 (GLP-2) analogue, the launch of teduglutide marks a new era in the treatment of short bowel syndrome.
In the future, teduglutide is expected to be applied to more patients and may provide new solutions for disease treatment in more related fields.
Summary
The approval of the listing of teduglutide not only brings new treatment options for SBS patients but also injects new hope into the global medical field.
By promoting intestinal adaptation and reducing dependence on parenteral nutrition, teduglutide is bringing a better quality of life to thousands of patients.
In the future, with the widespread application of teduglutide, we expect it to play a more important role in the treatment of short bowel syndrome and other intestinal-related diseases.
However, DengYue’s efforts to increase the affordability of the medicine are critical to ensuring that more patients benefit from it. So please feel free to contact us for Gattex Teduglutide.
Information from DengYueMedicine, HongKong Drug Wholesale Distributor offers this information as a guide, not a substitute for professional medical advice. Consult your doctor before any treatment.
